Home›Research›Compare›Semaglutide vs Tirzepatide
Peptide ComparisonSemaglutide vs Tirzepatide
Both are Metabolic peptides.
Semaglutide
GLP-1
Half-life: ~7 days (once-weekly dosing)
828 providers listed
Tirzepatide
Dual GLP-1
Half-life: ~5 days (once-weekly dosing)
577 providers listed
Semaglutide is carried by more providers on PeptideBase (828 vs 577); otherwise the two are closely matched on the measures we track.
Semaglutide
Half-life
~7 days (once-weekly dosing)
Tirzepatide
Half-life
~5 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| More provider options (828 vs 577) | Semaglutide |
| Dual GIP + GLP-1 receptor activation | Tirzepatide |
| Oral formulation available (Rybelsus) | Semaglutide |
| Greater avg. weight loss in phase 3 trials (SURMOUNT vs STEP) | Tirzepatide |
| Longer post-approval safety record (approved 2017 vs 2022) | Semaglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Semaglutide
Tirzepatide
Semaglutide
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.
+1 more
Tirzepatide
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospectiv…
+5 more
About Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.
About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Semaglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Tirzepatide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Semaglutide
Tirzepatide
Where to source these peptides
Semaglutide
828 listed
Browse directory →
Providers offeringTirzepatide
577 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated October 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Semaglutide vs Tirzepatide — Per-mg Price Comparison. Retrieved October 26, 2026, from https://peptidebase.io/peptides/compare/semaglutide/tirzepatide